


## BI 639667

<b>Cat. No.:</b>	HY-120588		
<b>CAS No.:</b>	1295298-26-8		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>18</sub> FN <sub>3</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	451.47		
<b>Target:</b>	CCR		
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : 10 mg/mL (22.15 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2150 mL	11.0749 mL	22.1499 mL
	5 mM	0.4430 mL	2.2150 mL	4.4300 mL
	10 mM	0.2215 mL	1.1075 mL	2.2150 mL

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC<sub>50</sub> of 1.8 nM in Ca<sup>2+</sup> flux assay<sup>[1]</sup>.

### IC<sub>50</sub> & Target

CCR1  
1.8 nM (IC<sub>50</sub>, in Ca<sup>2+</sup> flux assay)

---

## REFERENCES

---

[1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA